Compound News and Research

RSS

Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation

InSite Vision Incorporated, a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company's Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce the pain and inflammation associated with ocular surgery.

6 Jan 2011

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences, provided additional details from the recently completed Phase I clinical study for DB959, its PPAR delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes.

6 Jan 2011

Betulin in birch bark appears to provide metabolic benefits

An ingredient found in abundance in birch bark appears to have an array of metabolic benefits, according to new studies in animals that are reported in the January issue of Cell Metabolism, a Cell Press publication.

5 Jan 2011

VENENUM Biodesign relocates to new, state-of-the-art facility in Hamilton

VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today its relocation to a brand-new, state-of-the-art facility in Hamilton, NJ in Mercer County.

5 Jan 2011

AMRI, Genentech enter research and licensing collaboration

AMRI announced today a research and licensing agreement with Genentech, a member of the Roche Group, for a family of antibacterial compounds discovered from AMRI's proprietary research of its natural products sample collection.

5 Jan 2011

PanOptica completes $30 million Series A financing

PanOptica, Inc., a private biopharmaceutical company focused on licensing and developing innovative ophthalmology therapies, today announced that it has raised $30 million in a Series A financing. This round was led by SV Life Sciences and Third Rock Ventures.

4 Jan 2011

Primal fitness offer tips that help you get in shape for 2011

For your New Year's fitness resolution, why not turn to something new, but at the same time, very old? A new trend, called Primal fitness, involves practicing activities that our early hunter-gatherer ancestors would have experienced in the wild - movements such as walking, running, balancing, climbing, lifting, carrying, throwing and catching.

29 Dec 2010

Researchers develop breath-analysis technology for rapid detection of biomarkers

Researchers have overcome a fundamental obstacle in developing breath-analysis technology to rapidly diagnose patients by detecting chemical compounds called "biomarkers" in a person's respiration in real time.

29 Dec 2010

Proellex vaginal delivery exhibits four times activity of oral dose in animal study

Repros Therapeutics Inc. today announced it has completed two animal model studies of the use of Proellex® in a vaginally administered formulation that demonstrated effects on progesterone sensitive tissues equivalent to the highest oral dose formerly in development by the Company.

28 Dec 2010

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.

28 Dec 2010

Emergent initiates AV7909 Phase I trail for Anthrax vaccine

Emergent BioSolutions today announced the initiation of a Phase I clinical trial for NuThraxTM, also known as AV7909, with the dosing of the first subject.

27 Dec 2010

Growth hormone may be hazardous for middle aged and older people

A compound which acts in the opposite way as growth hormone can reverse some of the signs of aging, a research team that includes a Saint Louis University physician has shown. The finding may be counter-intuitive to some older adults who take growth hormone, thinking it will help revitalize them.

24 Dec 2010

Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA

Teva Pharmaceutical Industries Ltd. announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for a lower-volume (0.5mL) injection of glatiramer acetate. Copaxone® containing 20mg of glatiramer acetate in 1ml is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS).

24 Dec 2010

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Clinical Data, Inc., today announced that Santen Pharmaceutical Co., Ltd., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Clinical Data's highly selective adenosine A2A agonist, ATL313, for the indication of primary open angle glaucoma and ocular hypertension.

From Santen Pharmaceutical Co., Ltd. 23 Dec 2010

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Researchers at the Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, have found that an arsenic-based agent already FDA-approved for a type of leukemia may be helpful in another hard-to-treat cancer, Ewing's Sarcoma (ES). The research, based on animal studies, also suggests the drug might be beneficial in treating medulloblastoma, a highly malignant pediatric brain cancer.

23 Dec 2010

Research: Arsenic trioxide may benefit individuals with connective brain tumors

Arsenic is usually thought of as a poison. Despite this, it has been used in medicine for over 2000 years, and the arsenic compound arsenic trioxide (ATO) is FDA approved for the treatment of acute promyelocytic leukemia.

23 Dec 2010

Merrion, Novo Nordisk enter Collaboration and Option agreement for GIPET technology

Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the signing of a Collaboration and Option agreement with Novo Nordisk. The agreement will evaluate the ability of Merrion's patented GIPET® technology to boost the oral bioavailability of an undisclosed proprietary compound.

22 Dec 2010

Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease

Anavex Life Sciences Corp. announced today that it has filed the regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

21 Dec 2010

Biomagnification of nanomaterials in simple food chain demonstrated

An interdisciplinary team of researchers at UC Santa Barbara has produced a groundbreaking study of how nanoparticles are able to biomagnify in a simple microbial food chain.

21 Dec 2010

Wellcome Trust awards additional £390,000 for investigation of Allergen Delivery Inhibitors

Scientists at St George's, University of London and the University of Manchester have received an additional Seeding Drug Discovery award of £390,000 from the Wellcome Trust to explore a new class of experimental drugs that block the trigger of allergic reactions before symptoms show.

21 Dec 2010

Compound News and Research

Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

Betulin in birch bark appears to provide metabolic benefits

VENENUM Biodesign relocates to new, state-of-the-art facility in Hamilton

AMRI, Genentech enter research and licensing collaboration

PanOptica completes $30 million Series A financing

Primal fitness offer tips that help you get in shape for 2011

Researchers develop breath-analysis technology for rapid detection of biomarkers

Proellex vaginal delivery exhibits four times activity of oral dose in animal study

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

Emergent initiates AV7909 Phase I trail for Anthrax vaccine

Growth hormone may be hazardous for middle aged and older people

Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Research: Arsenic trioxide may benefit individuals with connective brain tumors

Merrion, Novo Nordisk enter Collaboration and Option agreement for GIPET technology

Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease

Biomagnification of nanomaterials in simple food chain demonstrated

Wellcome Trust awards additional £390,000 for investigation of Allergen Delivery Inhibitors

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News